Albert Chi-Yan Chan

Dr. Albert Chi-Yan Chan


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2022 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
CCChi Leung Chiang
Chi Leung Chiang
KCKeith Wan Hang Chiu
Keith Wan Hang Chiu
KCKenneth Sik Kwan Chan
Kenneth Sik Kwan Chan
FLFrancis Ann Shing Lee
Francis Ann Shing Lee
JLJames Chun Bong Li
James Chun Bong Li
ACAlbert Chi-Yan Chan
Albert Chi-Yan Chan

27 February 2013 in Liver Transplantation
Verified
Journal Article
Open access
PDF file
ACAlbert Chi-Yan Chan
Albert Chi-Yan Chan
SCSee Ching Chan
See Ching Chan
KCKenneth Siu Ho Chok
Kenneth Siu Ho Chok
TCTan To Cheung
Tan To Cheung
DCDai Wing Chiu
Dai Wing Chiu
CLChung Mau Lo
Chung Mau Lo
The objective of this study was to evaluate the efficacy of salvage liver transplantation (SLT), repeated hepatic resection (RR), and repeated radiofrequency ablation (rRFA) for patients with postoperative tumor recurrence. The optimal treatment strategy for patients with recurrent hepatocellular carcinoma (HCC) remains unclear. From January 1993 to September 2009, 532 patients underwent either hepatic resection or radiofrequency ablation (RFA) for HCC within the Milan criteria. In all, 219 patients experienced intrahepatic recurrence, and 87 were selected for SLT (n=19), RR (n=24), or rRFA (n=44). Their clinicopathological data were reviewed, and their survival outcomes were assessed with Kaplan-Meier methods. Seventy-four of 220 patients (33.6%) developed recurrent HCC within the Milan criteria. The median Model for End-Stage Liver Disease (MELD) scores for SLT, RR, and rRFA were 10.7, 7.2, and 8.3, respectively (P<0.001). The 1-, 3-, and 5-year tumor-free survival rates were 68.4%, 57.9%, and 57.9%, respectively, for SLT; 69.7%, 49.3%, and 49.3%, respectively, for RR; and 40.0%, 19.8%, and 10.6%, respectively, for rRFA (P=0.001). For recurrent HCC within the Milan criteria, the 1-, 3-, and 5-year tumor-free survival rates for SLT were all 60%; the corresponding rates were 70.2%, 48.0%, and 48.0% for RR and 41.0%, 20.3%, and 10.9% for RFA (P=0.004). After adjustments of the MELD score, the 5-year survival rates for SLT, RR, and rRFA were 50.0%, 48.0%, and 11.4%, respectively (P=0.003). A subgroup analysis showed that SLT and RR led to comparable survival outcomes, but both treatments led to significantly better survival outcomes than rRFA (P<0.001). In conclusion, SLT is an efficacious treatment for patients with recurrent HCC and should be considered when RR is not feasible. Liver Transpl 19:411–419, 2013. © 2013 AASLD.

12 November 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
CCChi-Leung Chiang
Chi-Leung Chiang
ACAlbert Chi-Yan Chan
Albert Chi-Yan Chan
KCKeith W. H. Chiu
Keith W. H. Chiu
FKFeng-Ming Kong
Feng-Ming Kong
Background: Current treatments of unresectable hepatocellular carcinoma (HCC) are trans-arterial chemo-embolization (TACE), stereotactic body radiotherapy (SBRT), and targeted therapy. However, these treatments are limited in efficacy and safety for patients with large tumor sizes. Here, we report a case series of combined SBRT and anti-PD-1 therapy in patients with unresectable HCC of large tumors. Methods: This is a retrospective case series of five patients with unresectable hepatocellular carcinoma who were treated with SBRT followed by anti-PD1 antibodies. Four patients (80%) received a single dose of TACE prior to SBRT. All patients had advanced HCC ineligible of curative intervention. In this study, we report their treatment responses according to modified RECIST (response evaluation criteria in solid tumor) criteria, 1-year local control (LC), progression-free survival (PFS), 1-year overall survival (OS) rate, and toxicities. Results: Among the five evaluated patients, three patients had underlying diseases of hepatitis B and four patients had Barcelona clinic liver cancer stage C. The median size of their tumors was 9.8 cm (range: 9–16.1 cm). In addition, two patients had tumor vascular thrombosis and one had extra-hepatic disease. Five out of five patients (100%) responded to treatment, with two complete responses (CR) and three partial responses (PR). Among the partial responders, one had a down-staged tumor that became amenable for radiofrequency ablation for tumor clearance. No patient developed tumor progression at the time of analysis during the median follow-up of 14.9 months (range 8.6–19 months). The median PFS was 14.9 months (range: 8.6–19 months); 1-year LC and OS rate were both 100%. One patient had grade ≥ 3 toxicities (pneumonitis and skin reaction). There was no classical radiation-induced liver disease. Conclusions: The results obtained from these 5 cases demonstrate impressive tumor control from the combination of SBRT and checkpoint inhibitors in patients with large tumors of advanced HCC. Further prospective trials are warranted.

1 June 2011 in Archives of Surgery
Verified
Journal Article
Open access
PDF file
ACAlbert Chi-Yan Chan
Albert Chi-Yan Chan
KCKenneth Siu Ho Chok
Kenneth Siu Ho Chok
WYWai Key Yuen
Wai Key Yuen
RPRonnie T. P. Poon
Ronnie T. P. Poon
CLChung Mau Lo
Chung Mau Lo
SFSheung Tat Fan
Sheung Tat Fan
Chronic hepatitis B virus (HBV) infection has become a global public health problem, with 350 million carriers worldwide.1 In areas where HBV is highly endemic, such as the Asia-Pacific region, chronic HBV infection is present in 80% to 90% of patients with hepatocellular carcinoma (HCC). Even in Western countries where HBV infection is less prevalent, it is still found in 16% to 60% of patients with HCC.2 Several studies have shown that, with the use of lamivudine, a nucleoside analogue, the risk of development of HCC and other cirrhotic-related complications was significantly reduced in those with chronic infection3-5 and even in cirrhotic patients.6 However, there is a scarcity of data on the role of antiviral therapy after curative treatment for HCC.7-9 Hepatectomy remains a standard curative treatment for HCC, but tumor recurrence is common, with approximately 50% of patients developing recurrent disease within 5 years.10-12 Further surgical treatment was often limited by impaired function of the remnant liver,13 and it remains uncertain whether antiviral therapy after initial treatment for HCC would prevent the remnant liver function from further deterioration and therefore increase the chances of these patients for future treatment. The aim of our study was to evaluate whether antiviral therapy after hepatectomy would improve the overall survival of patients with HBV-related HCC.

27 October 2011 in World Journal of Surgery
Verified
Journal Article
Open access
PDF file
ACAlbert Chi-Yan Chan
Albert Chi-Yan Chan
RPRonnie T. P. Poon
Ronnie T. P. Poon
TCTan To Cheung
Tan To Cheung
KCKenneth Siu Ho Chok
Kenneth Siu Ho Chok
SCSee Ching Chan
See Ching Chan
CLChung Mau Lo
Chung Mau Lo
Background: Tumor recurrence after resection of hepatocellular carcinoma is a common phenomenon. Re‐resection and radiofrequency ablation (RFA) are good options for treating recurrent HCC. This study compared the efficacy of these two modalities in the treatment of intrahepatic HCC recurrence after hepatectomy.Methods: From January 2001 to December 2008, a total of 179 patients developed intrahepatic HCC recurrence after hepatectomy. To treat the recurrence, 29 patients underwent re‐resection and 45 patients had RFA. Patient characteristics, clinicopathologic data, and survival outcomes were reviewed.Results: Child‐Pugh status, time to develop first recurrence (12.2 vs. 8.7 months), and recurrent tumor size (2.1 vs. 2.1 cm) were comparable for the two groups. Time to develop a second intrahepatic recurrence after re‐resection and RFA was 5.9 and 4.0 months respectively. The 1‐, 3‐, and 5‐year disease‐free survival rates were 41.4%, 24.2%, and 24.2% after re‐resection and 32.2%, 12.4%, and 9.3% after RFA (p = 0.14). The 1‐, 3‐, and 5‐year overall survival rates were 89.7%, 56.5%, and 35.2% after re‐resection and 83.7%, 43.1%, and 29.1% after RFA (p = 0.48). For the second recurrence, 33.3% of patients underwent a second round of RFA and 10.0% underwent a third resection.Conclusions: The two treatment modalities attained similar survival benefits in the management of recurrent HCC after hepatectomy. The high repeatability of RFA and that it can be delivered percutaneously render it a preferred treatment option for selected patients.

21 February 2025 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
CMChristian Tibor Josef Magyar
Christian Tibor Josef Magyar
LRLuckshi Rajendran
Luckshi Rajendran
ZLZhihao Li
Zhihao Li
VBVanessa Banz
Vanessa Banz
Arndt VogelArndt Vogel
Arndt Vogel
GSGonzalo Sapisochin
Gonzalo Sapisochin